We are live on ! Find out more
ANIP icon

ANI Pharmaceuticals

121 hedge funds and large institutions have $194M invested in ANI Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 45 increasing their positions, 38 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

18% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 38

5% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 20

2% less funds holding

Funds holding: 123121 (-2)

32% less capital invested

Capital invested by funds: $285M → $194M (-$91.5M)

36% less call options, than puts

Call options by funds: $4.58M | Put options by funds: $7.19M

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
121
Holders Change
-2
Holders Change %
-1.63%
% of All Funds
3.22%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
19
Increased
45
Reduced
38
Closed
20
Calls
$4.58M
Puts
$7.19M
Net Calls
-$2.62M
Net Calls Change
-$7.37M
Name Holding Trade Value Shares
Change
Change in
Stake
TAM
26
Third Avenue Management
New York
$1.69M
Ameriprise
27
Ameriprise
Minnesota
$1.45M +$63.8K +1,880 +5%
FSA
28
Franklin Street Advisors
North Carolina
$1.27M +$809K +23,845 +172%
TC
29
TFS Capital
Pennsylvania
$1.26M +$850K +25,052 +204%
BIM
30
BlackRock Investment Management
Delaware
$1.07M +$3.46K +102 +0.3%
MOACM
31
Mutual of America Capital Management
New York
$1.01M -$6.78K -200 -0.7%
Morgan Stanley
32
Morgan Stanley
New York
$939K +$683K +20,142 +260%
New York State Teachers Retirement System (NYSTRS)
33
New York State Teachers Retirement System (NYSTRS)
New York
$935K -$6.78K -200 -0.7%
CCM
34
Century Capital Management
Massachusetts
$889K -$3.29M -96,933 -79%
ARTA
35
A.R.T. Advisors
New York
$878K +$885K +26,093 New
Millennium Management
36
Millennium Management
New York
$842K -$78.6K -2,318 -8%
TCIM
37
TIAA CREF Investment Management
New York
$841K -$321K -9,463 -27%
CS
38
Credit Suisse
Switzerland
$783K -$360K -10,625 -31%
California Public Employees Retirement System
39
California Public Employees Retirement System
California
$734K -$47.5K -1,400 -6%
Invesco
40
Invesco
Georgia
$693K -$208K -6,133 -23%
Squarepoint
41
Squarepoint
New York
$628K +$261K +7,700 +70%
Prudential Financial
42
Prudential Financial
New Jersey
$620K +$13.6K +400 +2%
First Trust Advisors
43
First Trust Advisors
Illinois
$605K -$250K -7,382 -29%
California State Teachers Retirement System (CalSTRS)
44
California State Teachers Retirement System (CalSTRS)
California
$562K +$69.7K +2,054 +14%
CCM
45
Cadence Capital Management
Massachusetts
$552K +$307K +9,060 +124%
LSV Asset Management
46
LSV Asset Management
Illinois
$545K -$20.4K -600 -4%
Goldman Sachs
47
Goldman Sachs
New York
$535K +$116K +3,432 +28%
KCM
48
Kennedy Capital Management
Missouri
$505K +$509K +15,000 New
Citigroup
49
Citigroup
New York
$476K +$466K +13,729 +3,215%
Dimensional Fund Advisors
50
Dimensional Fund Advisors
Texas
$469K

ANIP Hedge Fund Activity: Q1 2016 in Review

121 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q1 2016, worth a combined $194M — down 32% from $285M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of ANIP and 19 opened new positions — a net loss of 1 holder — while 38 trimmed existing stakes and 45 added.

The largest buyer was Perceptive Advisors, adding an estimated $3.43M. The largest seller was Senzar Asset Management, cutting an estimated $7.8M.

  • 121 institutional investors held ANI Pharmaceuticals (ANIP) as of Q1 2016, down from 123 in Q4 2015.
  • Funds reported $194M of ANI Pharmaceuticals stock for Q1 2016, down 32% quarter-over-quarter.
  • 19 funds opened new ANI Pharmaceuticals positions in Q1 2016 and 20 closed out, a net change of -1 holder.
  • The largest ANI Pharmaceuticals buyer in Q1 2016 was Perceptive Advisors, an estimated $3.43M added.
  • The largest ANI Pharmaceuticals seller in Q1 2016 was Senzar Asset Management, an estimated $7.8M sold.

Based on aggregated 13F filings for Q1 2016.